Denis Barritault, PhD, OTR3 founder and President, co-inventor of RGTA, emeritus professor at the University of Paris XII, founder and director of the CRRET laboratory, a CNRS-University unit with a team of 50 members which D. Barritault built and led from 1985 until 2002. Co-author of more then 200 publications and inventor in 27 patents, he is also known for his pioneer work on growth factors with the first identification of FGF as skin and cornea healing agent and of HARP as a new growth factor. Laureate of the INSERM-French Academie des Sciences prize in 1995.

Véronique Chassefière, OTR3 full time biologist since start. Master in Science Biology. She has performed most of the studies on skin repair, in burns and ulcers. She is currently developing dosage methods for pharmacological studies.

Ketty Kichenin, PhD, OTR3 head of pharmacology and regulatory developments in OTR3 since 2005. 5 years post doc experience in pharmaceutical company before joining OTR3. She succeeded in finalizing all documents for successful application for clinical trials.

Directors and advisors Board : 21 experts
5 senior scientific, 6 professionals coming from global human health companies and 10 with business management backgrounds